nodes	percent_of_prediction	percent_of_DWPC	metapath
Azelastine—CYP1A1—Clobetasol propionate—psoriasis	0.079	0.108	CbGbCtD
Azelastine—CYP2A6—Methoxsalen—psoriasis	0.0486	0.0663	CbGbCtD
Azelastine—CYP1A1—Methoxsalen—psoriasis	0.0415	0.0567	CbGbCtD
Azelastine—CYP2C8—Tazarotene—psoriasis	0.0372	0.0507	CbGbCtD
Azelastine—CYP3A5—Beclomethasone—psoriasis	0.0359	0.0491	CbGbCtD
Azelastine—CYP1A2—Clobetasol propionate—psoriasis	0.0353	0.0482	CbGbCtD
Azelastine—CYP1A1—Cholecalciferol—psoriasis	0.0275	0.0375	CbGbCtD
Azelastine—CYP2A6—Prednisolone—psoriasis	0.0236	0.0322	CbGbCtD
Azelastine—CYP2B6—Cholecalciferol—psoriasis	0.0209	0.0286	CbGbCtD
Azelastine—CYP1A2—Methoxsalen—psoriasis	0.0185	0.0253	CbGbCtD
Azelastine—CYP2D6—Hydroxyurea—psoriasis	0.0167	0.0228	CbGbCtD
Azelastine—CYP2C8—Cholecalciferol—psoriasis	0.0159	0.0217	CbGbCtD
Azelastine—CYP3A5—Mycophenolate mofetil—psoriasis	0.0143	0.0195	CbGbCtD
Azelastine—CYP2A6—Dexamethasone—psoriasis	0.0139	0.019	CbGbCtD
Azelastine—CYP2C8—Mycophenolate mofetil—psoriasis	0.0137	0.0188	CbGbCtD
Azelastine—CYP2C19—Cholecalciferol—psoriasis	0.0133	0.0182	CbGbCtD
Azelastine—CYP3A4—Calcitriol—psoriasis	0.0125	0.0171	CbGbCtD
Azelastine—CYP1A1—Dexamethasone—psoriasis	0.0119	0.0162	CbGbCtD
Azelastine—CYP3A5—Hydrocortisone—psoriasis	0.0115	0.0157	CbGbCtD
Azelastine—CYP2C9—Cholecalciferol—psoriasis	0.0111	0.0151	CbGbCtD
Azelastine—CYP2C8—Hydrocortisone—psoriasis	0.011	0.0151	CbGbCtD
Azelastine—CYP3A5—Cyclosporine—psoriasis	0.0108	0.0148	CbGbCtD
Azelastine—CYP2C8—Cyclosporine—psoriasis	0.0104	0.0142	CbGbCtD
Azelastine—CYP2D6—Cholecalciferol—psoriasis	0.0101	0.0138	CbGbCtD
Azelastine—CYP3A4—Methoxsalen—psoriasis	0.00971	0.0133	CbGbCtD
Azelastine—ABCB1—Mycophenolate mofetil—psoriasis	0.00931	0.0127	CbGbCtD
Azelastine—CYP2C19—Prednisone—psoriasis	0.00922	0.0126	CbGbCtD
Azelastine—CYP2E1—Dexamethasone—psoriasis	0.00918	0.0125	CbGbCtD
Azelastine—CYP2B6—Dexamethasone—psoriasis	0.00906	0.0124	CbGbCtD
Azelastine—CYP2C19—Cyclosporine—psoriasis	0.00874	0.0119	CbGbCtD
Azelastine—ABCB1—Betamethasone—psoriasis	0.00799	0.0109	CbGbCtD
Azelastine—ABCB1—Prednisolone—psoriasis	0.00788	0.0108	CbGbCtD
Azelastine—ABCB1—Hydrocortisone—psoriasis	0.00747	0.0102	CbGbCtD
Azelastine—ABCB1—Prednisone—psoriasis	0.00744	0.0102	CbGbCtD
Azelastine—CYP2C9—Cyclosporine—psoriasis	0.00727	0.00993	CbGbCtD
Azelastine—CYP3A5—Dexamethasone—psoriasis	0.00714	0.00975	CbGbCtD
Azelastine—ABCB1—Cyclosporine—psoriasis	0.00705	0.00963	CbGbCtD
Azelastine—CYP2C8—Dexamethasone—psoriasis	0.00686	0.00937	CbGbCtD
Azelastine—CYP2D6—Cyclosporine—psoriasis	0.00665	0.00908	CbGbCtD
Azelastine—CYP3A4—Cholecalciferol—psoriasis	0.00643	0.00878	CbGbCtD
Azelastine—CYP2C19—Dexamethasone—psoriasis	0.00576	0.00786	CbGbCtD
Azelastine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00558	0.00762	CbGbCtD
Azelastine—CYP3A4—Triamcinolone—psoriasis	0.00558	0.00762	CbGbCtD
Azelastine—CYP2C9—Dexamethasone—psoriasis	0.00479	0.00654	CbGbCtD
Azelastine—CYP3A4—Betamethasone—psoriasis	0.00478	0.00653	CbGbCtD
Azelastine—CYP3A4—Prednisolone—psoriasis	0.00472	0.00645	CbGbCtD
Azelastine—ABCB1—Dexamethasone—psoriasis	0.00464	0.00634	CbGbCtD
Azelastine—CYP3A4—Hydrocortisone—psoriasis	0.00448	0.00611	CbGbCtD
Azelastine—CYP3A4—Prednisone—psoriasis	0.00446	0.00609	CbGbCtD
Azelastine—CYP2D6—Dexamethasone—psoriasis	0.00438	0.00598	CbGbCtD
Azelastine—CYP3A4—Cyclosporine—psoriasis	0.00423	0.00577	CbGbCtD
Azelastine—ABCB1—Methotrexate—psoriasis	0.00373	0.0051	CbGbCtD
Azelastine—CYP3A4—Dexamethasone—psoriasis	0.00278	0.0038	CbGbCtD
Azelastine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000127	0.00219	CbGpPWpGaD
Azelastine—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000127	0.00219	CbGpPWpGaD
Azelastine—ADRA1B—AMPK Signaling—LEP—psoriasis	0.000127	0.00218	CbGpPWpGaD
Azelastine—ABCB1—Allograft Rejection—IL13—psoriasis	0.000126	0.00217	CbGpPWpGaD
Azelastine—ADRA1B—LPA receptor mediated events—NFKBIA—psoriasis	0.000126	0.00216	CbGpPWpGaD
Azelastine—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000125	0.000595	CcSEcCtD
Azelastine—Asthma—Methotrexate—psoriasis	0.000124	0.000592	CcSEcCtD
Azelastine—Infection—Mycophenolate mofetil—psoriasis	0.000124	0.000591	CcSEcCtD
Azelastine—HRH1—GPCR ligand binding—HCAR2—psoriasis	0.000124	0.00213	CbGpPWpGaD
Azelastine—Hypertension—Prednisolone—psoriasis	0.000123	0.000587	CcSEcCtD
Azelastine—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—psoriasis	0.000123	0.00211	CbGpPWpGaD
Azelastine—Tachycardia—Mycophenolate mofetil—psoriasis	0.000122	0.00058	CcSEcCtD
Azelastine—Ill-defined disorder—Triamcinolone—psoriasis	0.000122	0.00058	CcSEcCtD
Azelastine—Hypertension—Hydrocortisone—psoriasis	0.00012	0.000573	CcSEcCtD
Azelastine—Vomiting—Hydroxyurea—psoriasis	0.00012	0.000572	CcSEcCtD
Azelastine—Discomfort—Prednisolone—psoriasis	0.00012	0.000572	CcSEcCtD
Azelastine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.00012	0.00205	CbGpPWpGaD
Azelastine—Rash—Hydroxyurea—psoriasis	0.000119	0.000567	CcSEcCtD
Azelastine—Dermatitis—Hydroxyurea—psoriasis	0.000119	0.000567	CcSEcCtD
Azelastine—Myalgia—Hydrocortisone—psoriasis	0.000118	0.000565	CcSEcCtD
Azelastine—Malaise—Triamcinolone—psoriasis	0.000118	0.000564	CcSEcCtD
Azelastine—Headache—Hydroxyurea—psoriasis	0.000118	0.000564	CcSEcCtD
Azelastine—Anxiety—Hydrocortisone—psoriasis	0.000118	0.000563	CcSEcCtD
Azelastine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000118	0.00202	CbGpPWpGaD
Azelastine—Vertigo—Triamcinolone—psoriasis	0.000118	0.000562	CcSEcCtD
Azelastine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000118	0.00202	CbGpPWpGaD
Azelastine—Discomfort—Hydrocortisone—psoriasis	0.000117	0.000558	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000116	0.000555	CcSEcCtD
Azelastine—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000116	0.002	CbGpPWpGaD
Azelastine—Anaphylactic shock—Prednisolone—psoriasis	0.000116	0.000555	CcSEcCtD
Azelastine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000116	0.00199	CbGpPWpGaD
Azelastine—Upper respiratory tract infection—Methotrexate—psoriasis	0.000115	0.000551	CcSEcCtD
Azelastine—Paraesthesia—Cyclosporine—psoriasis	0.000115	0.000547	CcSEcCtD
Azelastine—Cough—Triamcinolone—psoriasis	0.000114	0.000546	CcSEcCtD
Azelastine—Dyspnoea—Cyclosporine—psoriasis	0.000114	0.000544	CcSEcCtD
Azelastine—HRH3—Signaling Pathways—HCAR2—psoriasis	0.000114	0.00195	CbGpPWpGaD
Azelastine—Somnolence—Cyclosporine—psoriasis	0.000114	0.000542	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000114	0.000542	CcSEcCtD
Azelastine—Anaphylactic shock—Hydrocortisone—psoriasis	0.000114	0.000542	CcSEcCtD
Azelastine—Tachycardia—Prednisolone—psoriasis	0.000113	0.000541	CcSEcCtD
Azelastine—Asthenia—Mycophenolic acid—psoriasis	0.000113	0.000541	CcSEcCtD
Azelastine—Hypertension—Triamcinolone—psoriasis	0.000113	0.00054	CcSEcCtD
Azelastine—Infection—Hydrocortisone—psoriasis	0.000113	0.000538	CcSEcCtD
Azelastine—Nausea—Hydroxyurea—psoriasis	0.000112	0.000534	CcSEcCtD
Azelastine—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000112	0.000534	CcSEcCtD
Azelastine—Pruritus—Mycophenolic acid—psoriasis	0.000112	0.000533	CcSEcCtD
Azelastine—Myalgia—Triamcinolone—psoriasis	0.000112	0.000532	CcSEcCtD
Azelastine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000111	0.00191	CbGpPWpGaD
Azelastine—Eye disorder—Prednisone—psoriasis	0.000111	0.00053	CcSEcCtD
Azelastine—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000111	0.00053	CcSEcCtD
Azelastine—Tachycardia—Hydrocortisone—psoriasis	0.000111	0.000529	CcSEcCtD
Azelastine—Somnolence—Mycophenolate mofetil—psoriasis	0.000111	0.000529	CcSEcCtD
Azelastine—Flushing—Prednisone—psoriasis	0.00011	0.000527	CcSEcCtD
Azelastine—Ill-defined disorder—Dexamethasone—psoriasis	0.00011	0.000526	CcSEcCtD
Azelastine—Ill-defined disorder—Betamethasone—psoriasis	0.00011	0.000526	CcSEcCtD
Azelastine—Discomfort—Triamcinolone—psoriasis	0.00011	0.000526	CcSEcCtD
Azelastine—Fatigue—Cyclosporine—psoriasis	0.00011	0.000526	CcSEcCtD
Azelastine—HRH3—GPCR downstream signaling—CCL20—psoriasis	0.00011	0.00189	CbGpPWpGaD
Azelastine—Pain—Cyclosporine—psoriasis	0.000109	0.000521	CcSEcCtD
Azelastine—Constipation—Cyclosporine—psoriasis	0.000109	0.000521	CcSEcCtD
Azelastine—Dry mouth—Triamcinolone—psoriasis	0.000109	0.000521	CcSEcCtD
Azelastine—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000108	0.00186	CbGpPWpGaD
Azelastine—Diarrhoea—Mycophenolic acid—psoriasis	0.000108	0.000516	CcSEcCtD
Azelastine—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	0.000108	0.00186	CbGpPWpGaD
Azelastine—Conjunctivitis—Methotrexate—psoriasis	0.000108	0.000514	CcSEcCtD
Azelastine—Malaise—Dexamethasone—psoriasis	0.000107	0.000512	CcSEcCtD
Azelastine—Malaise—Betamethasone—psoriasis	0.000107	0.000512	CcSEcCtD
Azelastine—Anaphylactic shock—Triamcinolone—psoriasis	0.000107	0.00051	CcSEcCtD
Azelastine—HRH1—IL-4 Signaling Pathway—TYK2—psoriasis	0.000107	0.00183	CbGpPWpGaD
Azelastine—Vertigo—Dexamethasone—psoriasis	0.000107	0.00051	CcSEcCtD
Azelastine—Vertigo—Betamethasone—psoriasis	0.000107	0.00051	CcSEcCtD
Azelastine—Pain—Mycophenolate mofetil—psoriasis	0.000107	0.000509	CcSEcCtD
Azelastine—Constipation—Mycophenolate mofetil—psoriasis	0.000107	0.000509	CcSEcCtD
Azelastine—Infection—Triamcinolone—psoriasis	0.000106	0.000507	CcSEcCtD
Azelastine—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000106	0.00181	CbGpPWpGaD
Azelastine—Haematuria—Methotrexate—psoriasis	0.000106	0.000504	CcSEcCtD
Azelastine—Feeling abnormal—Cyclosporine—psoriasis	0.000105	0.000502	CcSEcCtD
Azelastine—CYP1A1—Oxidative Stress—NFKB1—psoriasis	0.000105	0.00181	CbGpPWpGaD
Azelastine—Gastrointestinal pain—Cyclosporine—psoriasis	0.000104	0.000499	CcSEcCtD
Azelastine—Dizziness—Mycophenolic acid—psoriasis	0.000104	0.000498	CcSEcCtD
Azelastine—Epistaxis—Methotrexate—psoriasis	0.000104	0.000498	CcSEcCtD
Azelastine—Paraesthesia—Prednisolone—psoriasis	0.000104	0.000498	CcSEcCtD
Azelastine—Tachycardia—Triamcinolone—psoriasis	0.000104	0.000498	CcSEcCtD
Azelastine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000104	0.00179	CbGpPWpGaD
Azelastine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000103	0.000494	CcSEcCtD
Azelastine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000103	0.00177	CbGpPWpGaD
Azelastine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000103	0.00049	CcSEcCtD
Azelastine—Hypertension—Dexamethasone—psoriasis	0.000103	0.00049	CcSEcCtD
Azelastine—Hypertension—Betamethasone—psoriasis	0.000103	0.00049	CcSEcCtD
Azelastine—Paraesthesia—Hydrocortisone—psoriasis	0.000102	0.000487	CcSEcCtD
Azelastine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000102	0.000486	CcSEcCtD
Azelastine—Myalgia—Betamethasone—psoriasis	0.000101	0.000483	CcSEcCtD
Azelastine—Myalgia—Dexamethasone—psoriasis	0.000101	0.000483	CcSEcCtD
Azelastine—Abdominal pain—Cyclosporine—psoriasis	0.000101	0.000482	CcSEcCtD
Azelastine—Body temperature increased—Cyclosporine—psoriasis	0.000101	0.000482	CcSEcCtD
Azelastine—Anxiety—Betamethasone—psoriasis	0.000101	0.000481	CcSEcCtD
Azelastine—Anxiety—Dexamethasone—psoriasis	0.000101	0.000481	CcSEcCtD
Azelastine—Vomiting—Mycophenolic acid—psoriasis	0.0001	0.000479	CcSEcCtD
Azelastine—Discomfort—Betamethasone—psoriasis	0.0001	0.000477	CcSEcCtD
Azelastine—Discomfort—Dexamethasone—psoriasis	0.0001	0.000477	CcSEcCtD
Azelastine—HRH3—Signaling by GPCR—CCL20—psoriasis	9.99e-05	0.00172	CbGpPWpGaD
Azelastine—Rash—Mycophenolic acid—psoriasis	9.96e-05	0.000475	CcSEcCtD
Azelastine—Dermatitis—Mycophenolic acid—psoriasis	9.95e-05	0.000475	CcSEcCtD
Azelastine—Pain—Prednisolone—psoriasis	9.94e-05	0.000474	CcSEcCtD
Azelastine—Headache—Mycophenolic acid—psoriasis	9.9e-05	0.000472	CcSEcCtD
Azelastine—Pharyngitis—Methotrexate—psoriasis	9.87e-05	0.000471	CcSEcCtD
Azelastine—Abdominal pain—Mycophenolate mofetil—psoriasis	9.85e-05	0.00047	CcSEcCtD
Azelastine—Body temperature increased—Mycophenolate mofetil—psoriasis	9.85e-05	0.00047	CcSEcCtD
Azelastine—HRH3—Signaling Pathways—TAGAP—psoriasis	9.85e-05	0.00169	CbGpPWpGaD
Azelastine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.84e-05	0.00169	CbGpPWpGaD
Azelastine—Fatigue—Hydrocortisone—psoriasis	9.79e-05	0.000467	CcSEcCtD
Azelastine—Vision blurred—Prednisone—psoriasis	9.76e-05	0.000466	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Triamcinolone—psoriasis	9.74e-05	0.000465	CcSEcCtD
Azelastine—Pain—Hydrocortisone—psoriasis	9.71e-05	0.000463	CcSEcCtD
Azelastine—Anaphylactic shock—Betamethasone—psoriasis	9.7e-05	0.000463	CcSEcCtD
Azelastine—Anaphylactic shock—Dexamethasone—psoriasis	9.7e-05	0.000463	CcSEcCtD
Azelastine—Infection—Betamethasone—psoriasis	9.64e-05	0.00046	CcSEcCtD
Azelastine—Infection—Dexamethasone—psoriasis	9.64e-05	0.00046	CcSEcCtD
Azelastine—Ill-defined disorder—Prednisone—psoriasis	9.61e-05	0.000458	CcSEcCtD
Azelastine—Paraesthesia—Triamcinolone—psoriasis	9.6e-05	0.000458	CcSEcCtD
Azelastine—Feeling abnormal—Prednisolone—psoriasis	9.58e-05	0.000457	CcSEcCtD
Azelastine—Visual impairment—Methotrexate—psoriasis	9.58e-05	0.000457	CcSEcCtD
Azelastine—Dyspnoea—Triamcinolone—psoriasis	9.53e-05	0.000455	CcSEcCtD
Azelastine—Agitation—Prednisone—psoriasis	9.51e-05	0.000454	CcSEcCtD
Azelastine—Tachycardia—Betamethasone—psoriasis	9.47e-05	0.000452	CcSEcCtD
Azelastine—Tachycardia—Dexamethasone—psoriasis	9.47e-05	0.000452	CcSEcCtD
Azelastine—Hypersensitivity—Cyclosporine—psoriasis	9.41e-05	0.000449	CcSEcCtD
Azelastine—Nausea—Mycophenolic acid—psoriasis	9.38e-05	0.000448	CcSEcCtD
Azelastine—Feeling abnormal—Hydrocortisone—psoriasis	9.36e-05	0.000447	CcSEcCtD
Azelastine—Malaise—Prednisone—psoriasis	9.34e-05	0.000445	CcSEcCtD
Azelastine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	9.33e-05	0.0016	CbGpPWpGaD
Azelastine—Vertigo—Prednisone—psoriasis	9.3e-05	0.000444	CcSEcCtD
Azelastine—Eye disorder—Methotrexate—psoriasis	9.29e-05	0.000443	CcSEcCtD
Azelastine—Gastrointestinal pain—Hydrocortisone—psoriasis	9.29e-05	0.000443	CcSEcCtD
Azelastine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	9.22e-05	0.00158	CbGpPWpGaD
Azelastine—Fatigue—Triamcinolone—psoriasis	9.22e-05	0.00044	CcSEcCtD
Azelastine—Hypersensitivity—Mycophenolate mofetil—psoriasis	9.18e-05	0.000438	CcSEcCtD
Azelastine—Asthenia—Cyclosporine—psoriasis	9.17e-05	0.000437	CcSEcCtD
Azelastine—Pain—Triamcinolone—psoriasis	9.14e-05	0.000436	CcSEcCtD
Azelastine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	9.1e-05	0.00156	CbGpPWpGaD
Azelastine—Pruritus—Cyclosporine—psoriasis	9.04e-05	0.000431	CcSEcCtD
Azelastine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	8.98e-05	0.00154	CbGpPWpGaD
Azelastine—Body temperature increased—Hydrocortisone—psoriasis	8.98e-05	0.000428	CcSEcCtD
Azelastine—Abdominal pain—Hydrocortisone—psoriasis	8.98e-05	0.000428	CcSEcCtD
Azelastine—ADRA1B—LPA receptor mediated events—CXCL8—psoriasis	8.97e-05	0.00154	CbGpPWpGaD
Azelastine—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	8.97e-05	0.00154	CbGpPWpGaD
Azelastine—Asthenia—Mycophenolate mofetil—psoriasis	8.94e-05	0.000427	CcSEcCtD
Azelastine—Hypertension—Prednisone—psoriasis	8.94e-05	0.000426	CcSEcCtD
Azelastine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.89e-05	0.00153	CbGpPWpGaD
Azelastine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	8.84e-05	0.00152	CbGpPWpGaD
Azelastine—Musculoskeletal discomfort—Dexamethasone—psoriasis	8.84e-05	0.000422	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Betamethasone—psoriasis	8.84e-05	0.000422	CcSEcCtD
Azelastine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	8.83e-05	0.00152	CbGpPWpGaD
Azelastine—Pruritus—Mycophenolate mofetil—psoriasis	8.82e-05	0.000421	CcSEcCtD
Azelastine—Myalgia—Prednisone—psoriasis	8.81e-05	0.000421	CcSEcCtD
Azelastine—Feeling abnormal—Triamcinolone—psoriasis	8.81e-05	0.00042	CcSEcCtD
Azelastine—Anxiety—Prednisone—psoriasis	8.78e-05	0.000419	CcSEcCtD
Azelastine—Diarrhoea—Cyclosporine—psoriasis	8.74e-05	0.000417	CcSEcCtD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	8.74e-05	0.0015	CbGpPWpGaD
Azelastine—Paraesthesia—Betamethasone—psoriasis	8.71e-05	0.000416	CcSEcCtD
Azelastine—Paraesthesia—Dexamethasone—psoriasis	8.71e-05	0.000416	CcSEcCtD
Azelastine—Discomfort—Prednisone—psoriasis	8.71e-05	0.000416	CcSEcCtD
Azelastine—HRH3—G alpha (i) signalling events—CXCL8—psoriasis	8.68e-05	0.00149	CbGpPWpGaD
Azelastine—Hypersensitivity—Prednisolone—psoriasis	8.57e-05	0.000409	CcSEcCtD
Azelastine—Diarrhoea—Mycophenolate mofetil—psoriasis	8.53e-05	0.000407	CcSEcCtD
Azelastine—Dysgeusia—Methotrexate—psoriasis	8.47e-05	0.000404	CcSEcCtD
Azelastine—Body temperature increased—Triamcinolone—psoriasis	8.45e-05	0.000403	CcSEcCtD
Azelastine—Dizziness—Cyclosporine—psoriasis	8.45e-05	0.000403	CcSEcCtD
Azelastine—Anaphylactic shock—Prednisone—psoriasis	8.45e-05	0.000403	CcSEcCtD
Azelastine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	8.45e-05	0.00145	CbGpPWpGaD
Azelastine—Infection—Prednisone—psoriasis	8.39e-05	0.000401	CcSEcCtD
Azelastine—Back pain—Methotrexate—psoriasis	8.37e-05	0.000399	CcSEcCtD
Azelastine—Hypersensitivity—Hydrocortisone—psoriasis	8.37e-05	0.000399	CcSEcCtD
Azelastine—Fatigue—Betamethasone—psoriasis	8.37e-05	0.000399	CcSEcCtD
Azelastine—Fatigue—Dexamethasone—psoriasis	8.37e-05	0.000399	CcSEcCtD
Azelastine—ADRA1B—LPA receptor mediated events—JUN—psoriasis	8.34e-05	0.00143	CbGpPWpGaD
Azelastine—HRH1—IL-4 Signaling Pathway—NFKB1—psoriasis	8.33e-05	0.00143	CbGpPWpGaD
Azelastine—Pain—Betamethasone—psoriasis	8.3e-05	0.000396	CcSEcCtD
Azelastine—Pain—Dexamethasone—psoriasis	8.3e-05	0.000396	CcSEcCtD
Azelastine—Tachycardia—Prednisone—psoriasis	8.25e-05	0.000393	CcSEcCtD
Azelastine—Dizziness—Mycophenolate mofetil—psoriasis	8.24e-05	0.000393	CcSEcCtD
Azelastine—Vision blurred—Methotrexate—psoriasis	8.15e-05	0.000389	CcSEcCtD
Azelastine—Asthenia—Hydrocortisone—psoriasis	8.15e-05	0.000389	CcSEcCtD
Azelastine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	8.13e-05	0.0014	CbGpPWpGaD
Azelastine—Vomiting—Cyclosporine—psoriasis	8.12e-05	0.000388	CcSEcCtD
Azelastine—Rash—Cyclosporine—psoriasis	8.06e-05	0.000384	CcSEcCtD
Azelastine—Dermatitis—Cyclosporine—psoriasis	8.05e-05	0.000384	CcSEcCtD
Azelastine—Pruritus—Hydrocortisone—psoriasis	8.03e-05	0.000383	CcSEcCtD
Azelastine—ADRA1B—LPA receptor mediated events—NFKB1—psoriasis	8.03e-05	0.00138	CbGpPWpGaD
Azelastine—Ill-defined disorder—Methotrexate—psoriasis	8.03e-05	0.000383	CcSEcCtD
Azelastine—Headache—Cyclosporine—psoriasis	8.01e-05	0.000382	CcSEcCtD
Azelastine—Feeling abnormal—Betamethasone—psoriasis	8e-05	0.000381	CcSEcCtD
Azelastine—Feeling abnormal—Dexamethasone—psoriasis	8e-05	0.000381	CcSEcCtD
Azelastine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.96e-05	0.00137	CbGpPWpGaD
Azelastine—Gastrointestinal pain—Dexamethasone—psoriasis	7.93e-05	0.000379	CcSEcCtD
Azelastine—Gastrointestinal pain—Betamethasone—psoriasis	7.93e-05	0.000379	CcSEcCtD
Azelastine—Vomiting—Mycophenolate mofetil—psoriasis	7.93e-05	0.000378	CcSEcCtD
Azelastine—ABCB1—Allograft Rejection—IL10—psoriasis	7.91e-05	0.00136	CbGpPWpGaD
Azelastine—Hypersensitivity—Triamcinolone—psoriasis	7.88e-05	0.000376	CcSEcCtD
Azelastine—Rash—Mycophenolate mofetil—psoriasis	7.86e-05	0.000375	CcSEcCtD
Azelastine—Dermatitis—Mycophenolate mofetil—psoriasis	7.85e-05	0.000375	CcSEcCtD
Azelastine—Headache—Mycophenolate mofetil—psoriasis	7.81e-05	0.000373	CcSEcCtD
Azelastine—Malaise—Methotrexate—psoriasis	7.8e-05	0.000372	CcSEcCtD
Azelastine—Vertigo—Methotrexate—psoriasis	7.77e-05	0.000371	CcSEcCtD
Azelastine—Diarrhoea—Hydrocortisone—psoriasis	7.77e-05	0.000371	CcSEcCtD
Azelastine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	7.76e-05	0.00133	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—HCAR2—psoriasis	7.73e-05	0.00133	CbGpPWpGaD
Azelastine—Musculoskeletal discomfort—Prednisone—psoriasis	7.7e-05	0.000367	CcSEcCtD
Azelastine—ABCB1—Allograft Rejection—IL4—psoriasis	7.7e-05	0.00132	CbGpPWpGaD
Azelastine—Dizziness—Prednisolone—psoriasis	7.69e-05	0.000367	CcSEcCtD
Azelastine—Asthenia—Triamcinolone—psoriasis	7.67e-05	0.000366	CcSEcCtD
Azelastine—Abdominal pain—Betamethasone—psoriasis	7.67e-05	0.000366	CcSEcCtD
Azelastine—Abdominal pain—Dexamethasone—psoriasis	7.67e-05	0.000366	CcSEcCtD
Azelastine—Body temperature increased—Dexamethasone—psoriasis	7.67e-05	0.000366	CcSEcCtD
Azelastine—Body temperature increased—Betamethasone—psoriasis	7.67e-05	0.000366	CcSEcCtD
Azelastine—Nausea—Cyclosporine—psoriasis	7.59e-05	0.000362	CcSEcCtD
Azelastine—Paraesthesia—Prednisone—psoriasis	7.59e-05	0.000362	CcSEcCtD
Azelastine—Pruritus—Triamcinolone—psoriasis	7.57e-05	0.000361	CcSEcCtD
Azelastine—Cough—Methotrexate—psoriasis	7.55e-05	0.00036	CcSEcCtD
Azelastine—ABCB1—Allograft Rejection—HLA-B—psoriasis	7.53e-05	0.00129	CbGpPWpGaD
Azelastine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	7.52e-05	0.00129	CbGpPWpGaD
Azelastine—Dizziness—Hydrocortisone—psoriasis	7.51e-05	0.000358	CcSEcCtD
Azelastine—HRH1—IL-4 Signaling Pathway—STAT3—psoriasis	7.48e-05	0.00128	CbGpPWpGaD
Azelastine—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	7.47e-05	0.00128	CbGpPWpGaD
Azelastine—Nausea—Mycophenolate mofetil—psoriasis	7.4e-05	0.000353	CcSEcCtD
Azelastine—Myalgia—Methotrexate—psoriasis	7.37e-05	0.000351	CcSEcCtD
Azelastine—Chest pain—Methotrexate—psoriasis	7.37e-05	0.000351	CcSEcCtD
Azelastine—KCNH2—SIDS Susceptibility Pathways—CXCL8—psoriasis	7.36e-05	0.00126	CbGpPWpGaD
Azelastine—Rash—Prednisolone—psoriasis	7.33e-05	0.00035	CcSEcCtD
Azelastine—Dermatitis—Prednisolone—psoriasis	7.33e-05	0.000349	CcSEcCtD
Azelastine—Fatigue—Prednisone—psoriasis	7.29e-05	0.000348	CcSEcCtD
Azelastine—Headache—Prednisolone—psoriasis	7.28e-05	0.000348	CcSEcCtD
Azelastine—Discomfort—Methotrexate—psoriasis	7.28e-05	0.000347	CcSEcCtD
Azelastine—Constipation—Prednisone—psoriasis	7.23e-05	0.000345	CcSEcCtD
Azelastine—Vomiting—Hydrocortisone—psoriasis	7.22e-05	0.000345	CcSEcCtD
Azelastine—Rash—Hydrocortisone—psoriasis	7.16e-05	0.000342	CcSEcCtD
Azelastine—Dermatitis—Hydrocortisone—psoriasis	7.15e-05	0.000341	CcSEcCtD
Azelastine—Confusional state—Methotrexate—psoriasis	7.12e-05	0.00034	CcSEcCtD
Azelastine—Headache—Hydrocortisone—psoriasis	7.11e-05	0.000339	CcSEcCtD
Azelastine—ADRA1B—GPCR ligand binding—CCL20—psoriasis	7.11e-05	0.00122	CbGpPWpGaD
Azelastine—Dizziness—Triamcinolone—psoriasis	7.07e-05	0.000337	CcSEcCtD
Azelastine—Anaphylactic shock—Methotrexate—psoriasis	7.06e-05	0.000337	CcSEcCtD
Azelastine—ADRA1B—Signaling by GPCR—HCAR2—psoriasis	7.02e-05	0.00121	CbGpPWpGaD
Azelastine—Infection—Methotrexate—psoriasis	7.02e-05	0.000335	CcSEcCtD
Azelastine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	7.01e-05	0.0012	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—HCAR2—psoriasis	7e-05	0.0012	CbGpPWpGaD
Azelastine—ABCB1—Allograft Rejection—HLA-A—psoriasis	6.97e-05	0.0012	CbGpPWpGaD
Azelastine—Feeling abnormal—Prednisone—psoriasis	6.96e-05	0.000332	CcSEcCtD
Azelastine—Asthenia—Betamethasone—psoriasis	6.96e-05	0.000332	CcSEcCtD
Azelastine—Asthenia—Dexamethasone—psoriasis	6.96e-05	0.000332	CcSEcCtD
Azelastine—Gastrointestinal pain—Prednisone—psoriasis	6.91e-05	0.00033	CcSEcCtD
Azelastine—Nausea—Prednisolone—psoriasis	6.91e-05	0.00033	CcSEcCtD
Azelastine—HRH3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	6.91e-05	0.00119	CbGpPWpGaD
Azelastine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	6.89e-05	0.00118	CbGpPWpGaD
Azelastine—Pruritus—Dexamethasone—psoriasis	6.86e-05	0.000328	CcSEcCtD
Azelastine—Pruritus—Betamethasone—psoriasis	6.86e-05	0.000328	CcSEcCtD
Azelastine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.86e-05	0.00118	CbGpPWpGaD
Azelastine—KCNH2—SIDS Susceptibility Pathways—JUN—psoriasis	6.85e-05	0.00118	CbGpPWpGaD
Azelastine—Vomiting—Triamcinolone—psoriasis	6.8e-05	0.000324	CcSEcCtD
Azelastine—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	6.78e-05	0.00116	CbGpPWpGaD
Azelastine—Nausea—Hydrocortisone—psoriasis	6.75e-05	0.000322	CcSEcCtD
Azelastine—Rash—Triamcinolone—psoriasis	6.74e-05	0.000322	CcSEcCtD
Azelastine—Dermatitis—Triamcinolone—psoriasis	6.74e-05	0.000321	CcSEcCtD
Azelastine—Headache—Triamcinolone—psoriasis	6.7e-05	0.00032	CcSEcCtD
Azelastine—Body temperature increased—Prednisone—psoriasis	6.68e-05	0.000319	CcSEcCtD
Azelastine—Abdominal pain—Prednisone—psoriasis	6.68e-05	0.000319	CcSEcCtD
Azelastine—Diarrhoea—Betamethasone—psoriasis	6.64e-05	0.000317	CcSEcCtD
Azelastine—Diarrhoea—Dexamethasone—psoriasis	6.64e-05	0.000317	CcSEcCtD
Azelastine—KCNH2—SIDS Susceptibility Pathways—NFKB1—psoriasis	6.59e-05	0.00113	CbGpPWpGaD
Azelastine—Musculoskeletal discomfort—Methotrexate—psoriasis	6.43e-05	0.000307	CcSEcCtD
Azelastine—HRH1—GPCR ligand binding—CCL20—psoriasis	6.43e-05	0.0011	CbGpPWpGaD
Azelastine—Dizziness—Dexamethasone—psoriasis	6.42e-05	0.000306	CcSEcCtD
Azelastine—Dizziness—Betamethasone—psoriasis	6.42e-05	0.000306	CcSEcCtD
Azelastine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	6.37e-05	0.00109	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—HCAR2—psoriasis	6.36e-05	0.00109	CbGpPWpGaD
Azelastine—Nausea—Triamcinolone—psoriasis	6.35e-05	0.000303	CcSEcCtD
Azelastine—Paraesthesia—Methotrexate—psoriasis	6.34e-05	0.000303	CcSEcCtD
Azelastine—Dyspnoea—Methotrexate—psoriasis	6.3e-05	0.0003	CcSEcCtD
Azelastine—Somnolence—Methotrexate—psoriasis	6.28e-05	0.0003	CcSEcCtD
Azelastine—Hypersensitivity—Prednisone—psoriasis	6.23e-05	0.000297	CcSEcCtD
Azelastine—Vomiting—Betamethasone—psoriasis	6.17e-05	0.000294	CcSEcCtD
Azelastine—Vomiting—Dexamethasone—psoriasis	6.17e-05	0.000294	CcSEcCtD
Azelastine—Rash—Dexamethasone—psoriasis	6.12e-05	0.000292	CcSEcCtD
Azelastine—Rash—Betamethasone—psoriasis	6.12e-05	0.000292	CcSEcCtD
Azelastine—Dermatitis—Dexamethasone—psoriasis	6.11e-05	0.000292	CcSEcCtD
Azelastine—Dermatitis—Betamethasone—psoriasis	6.11e-05	0.000292	CcSEcCtD
Azelastine—Fatigue—Methotrexate—psoriasis	6.09e-05	0.00029	CcSEcCtD
Azelastine—Headache—Dexamethasone—psoriasis	6.08e-05	0.00029	CcSEcCtD
Azelastine—Headache—Betamethasone—psoriasis	6.08e-05	0.00029	CcSEcCtD
Azelastine—Asthenia—Prednisone—psoriasis	6.06e-05	0.000289	CcSEcCtD
Azelastine—Pain—Methotrexate—psoriasis	6.04e-05	0.000288	CcSEcCtD
Azelastine—KCNH2—SIDS Susceptibility Pathways—VEGFA—psoriasis	5.98e-05	0.00103	CbGpPWpGaD
Azelastine—Pruritus—Prednisone—psoriasis	5.98e-05	0.000285	CcSEcCtD
Azelastine—HRH3—Signaling Pathways—CCL20—psoriasis	5.9e-05	0.00101	CbGpPWpGaD
Azelastine—Feeling abnormal—Methotrexate—psoriasis	5.82e-05	0.000278	CcSEcCtD
Azelastine—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	5.81e-05	0.000998	CbGpPWpGaD
Azelastine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	5.81e-05	0.000998	CbGpPWpGaD
Azelastine—Diarrhoea—Prednisone—psoriasis	5.78e-05	0.000276	CcSEcCtD
Azelastine—Gastrointestinal pain—Methotrexate—psoriasis	5.77e-05	0.000276	CcSEcCtD
Azelastine—Nausea—Dexamethasone—psoriasis	5.76e-05	0.000275	CcSEcCtD
Azelastine—Nausea—Betamethasone—psoriasis	5.76e-05	0.000275	CcSEcCtD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	5.73e-05	0.000983	CbGpPWpGaD
Azelastine—Dizziness—Prednisone—psoriasis	5.59e-05	0.000267	CcSEcCtD
Azelastine—Body temperature increased—Methotrexate—psoriasis	5.58e-05	0.000266	CcSEcCtD
Azelastine—Abdominal pain—Methotrexate—psoriasis	5.58e-05	0.000266	CcSEcCtD
Azelastine—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	5.45e-05	0.000935	CbGpPWpGaD
Azelastine—Vomiting—Prednisone—psoriasis	5.37e-05	0.000256	CcSEcCtD
Azelastine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	5.33e-05	0.000915	CbGpPWpGaD
Azelastine—Rash—Prednisone—psoriasis	5.33e-05	0.000254	CcSEcCtD
Azelastine—Dermatitis—Prednisone—psoriasis	5.32e-05	0.000254	CcSEcCtD
Azelastine—Headache—Prednisone—psoriasis	5.29e-05	0.000253	CcSEcCtD
Azelastine—HRH3—GPCR ligand binding—CXCL8—psoriasis	5.26e-05	0.000903	CbGpPWpGaD
Azelastine—Hypersensitivity—Methotrexate—psoriasis	5.2e-05	0.000248	CcSEcCtD
Azelastine—ADRA1B—AMPK Signaling—TP53—psoriasis	5.18e-05	0.00089	CbGpPWpGaD
Azelastine—KCNH2—SIDS Susceptibility Pathways—TNF—psoriasis	5.13e-05	0.00088	CbGpPWpGaD
Azelastine—Asthenia—Methotrexate—psoriasis	5.07e-05	0.000242	CcSEcCtD
Azelastine—CYP2A6—Metabolism—NDUFA5—psoriasis	5.06e-05	0.000869	CbGpPWpGaD
Azelastine—Nausea—Prednisone—psoriasis	5.02e-05	0.000239	CcSEcCtD
Azelastine—Pruritus—Methotrexate—psoriasis	5e-05	0.000238	CcSEcCtD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.95e-05	0.00085	CbGpPWpGaD
Azelastine—Diarrhoea—Methotrexate—psoriasis	4.83e-05	0.000231	CcSEcCtD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.76e-05	0.000818	CbGpPWpGaD
Azelastine—Dizziness—Methotrexate—psoriasis	4.67e-05	0.000223	CcSEcCtD
Azelastine—ABCB1—Allograft Rejection—IFNG—psoriasis	4.65e-05	0.000799	CbGpPWpGaD
Azelastine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.64e-05	0.000797	CbGpPWpGaD
Azelastine—Vomiting—Methotrexate—psoriasis	4.49e-05	0.000214	CcSEcCtD
Azelastine—Rash—Methotrexate—psoriasis	4.45e-05	0.000212	CcSEcCtD
Azelastine—Dermatitis—Methotrexate—psoriasis	4.45e-05	0.000212	CcSEcCtD
Azelastine—Headache—Methotrexate—psoriasis	4.42e-05	0.000211	CcSEcCtD
Azelastine—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.33e-05	0.000743	CbGpPWpGaD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.32e-05	0.000742	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—CYP2S1—psoriasis	4.3e-05	0.000739	CbGpPWpGaD
Azelastine—Nausea—Methotrexate—psoriasis	4.19e-05	0.0002	CcSEcCtD
Azelastine—ADRA1B—Signaling Pathways—HCAR2—psoriasis	4.15e-05	0.000712	CbGpPWpGaD
Azelastine—KCNH2—SIDS Susceptibility Pathways—IL6—psoriasis	4.14e-05	0.00071	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—NDUFA5—psoriasis	4.08e-05	0.000701	CbGpPWpGaD
Azelastine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.06e-05	0.000697	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—CCL20—psoriasis	4.02e-05	0.000689	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—NDUFA5—psoriasis	4e-05	0.000686	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—NDUFA5—psoriasis	3.99e-05	0.000685	CbGpPWpGaD
Azelastine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	3.91e-05	0.000671	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—NDUFA5—psoriasis	3.77e-05	0.000647	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—HCAR2—psoriasis	3.75e-05	0.000645	CbGpPWpGaD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.71e-05	0.000636	CbGpPWpGaD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.71e-05	0.000636	CbGpPWpGaD
Azelastine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	3.67e-05	0.000631	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—CCL20—psoriasis	3.65e-05	0.000626	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—CCL20—psoriasis	3.64e-05	0.000624	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TAGAP—psoriasis	3.6e-05	0.000617	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.56e-05	0.000612	CbGpPWpGaD
Azelastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	3.54e-05	0.000607	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.51e-05	0.000603	CbGpPWpGaD
Azelastine—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.51e-05	0.000603	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—CYP2S1—psoriasis	3.47e-05	0.000596	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—NDUFA5—psoriasis	3.46e-05	0.000593	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—CYP2S1—psoriasis	3.4e-05	0.000584	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—CYP2S1—psoriasis	3.39e-05	0.000582	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—CCL20—psoriasis	3.3e-05	0.000567	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TAGAP—psoriasis	3.26e-05	0.000559	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—SOCS1—psoriasis	3.25e-05	0.000558	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.22e-05	0.000553	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—CYP2S1—psoriasis	3.21e-05	0.00055	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—TYK2—psoriasis	3.1e-05	0.000532	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—NDUFA5—psoriasis	3.08e-05	0.00053	CbGpPWpGaD
Azelastine—ABCB1—Allograft Rejection—TNF—psoriasis	3.01e-05	0.000517	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—NDUFA5—psoriasis	3.01e-05	0.000517	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.99e-05	0.000514	CbGpPWpGaD
Azelastine—HRH3—GPCR downstream signaling—CXCL8—psoriasis	2.97e-05	0.00051	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—CYP2S1—psoriasis	2.94e-05	0.000505	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.88e-05	0.000494	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—NDUFA5—psoriasis	2.84e-05	0.000487	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—NDUFA5—psoriasis	2.81e-05	0.000483	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.8e-05	0.00048	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—CXCL8—psoriasis	2.7e-05	0.000463	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.67e-05	0.000458	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CYP2S1—psoriasis	2.62e-05	0.00045	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.62e-05	0.00045	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CYP2S1—psoriasis	2.56e-05	0.00044	CbGpPWpGaD
Azelastine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.52e-05	0.000433	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CYP2S1—psoriasis	2.41e-05	0.000414	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—NDUFA5—psoriasis	2.4e-05	0.000413	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—LEP—psoriasis	2.4e-05	0.000412	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—APOE—psoriasis	2.4e-05	0.000412	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CYP2S1—psoriasis	2.39e-05	0.000411	CbGpPWpGaD
Azelastine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.28e-05	0.000392	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.24e-05	0.000385	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—NFKBIA—psoriasis	2.24e-05	0.000384	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CCL20—psoriasis	2.15e-05	0.00037	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—CARM1—psoriasis	2.1e-05	0.000361	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CYP2S1—psoriasis	2.04e-05	0.000351	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.98e-05	0.000341	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CCL20—psoriasis	1.95e-05	0.000335	CbGpPWpGaD
Azelastine—ADRA1B—GPCR ligand binding—CXCL8—psoriasis	1.92e-05	0.000329	CbGpPWpGaD
Azelastine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.91e-05	0.000328	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.91e-05	0.000328	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.85e-05	0.000318	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—TYK2—psoriasis	1.83e-05	0.000314	CbGpPWpGaD
Azelastine—HRH1—GPCR ligand binding—CXCL8—psoriasis	1.74e-05	0.000298	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.73e-05	0.000298	CbGpPWpGaD
Azelastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.73e-05	0.000297	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—CARM1—psoriasis	1.7e-05	0.000291	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.68e-05	0.000288	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—CARM1—psoriasis	1.66e-05	0.000285	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—CARM1—psoriasis	1.66e-05	0.000284	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—CXCL8—psoriasis	1.59e-05	0.000274	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.58e-05	0.000271	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—CARM1—psoriasis	1.57e-05	0.000269	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.54e-05	0.000264	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—IL6—psoriasis	1.52e-05	0.00026	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.49e-05	0.000255	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—JUN—psoriasis	1.48e-05	0.000254	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.46e-05	0.000251	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—CARM1—psoriasis	1.44e-05	0.000246	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—NFKB1—psoriasis	1.43e-05	0.000245	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.37e-05	0.000236	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.34e-05	0.00023	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.31e-05	0.000225	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—VEGFA—psoriasis	1.29e-05	0.000222	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—CAT—psoriasis	1.29e-05	0.000222	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—STAT3—psoriasis	1.28e-05	0.00022	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CARM1—psoriasis	1.28e-05	0.00022	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.25e-05	0.000215	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CARM1—psoriasis	1.25e-05	0.000215	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.2e-05	0.000206	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—SOCS1—psoriasis	1.19e-05	0.000204	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CARM1—psoriasis	1.18e-05	0.000202	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CARM1—psoriasis	1.17e-05	0.000201	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—TYK2—psoriasis	1.13e-05	0.000194	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.09e-05	0.000187	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—CXCL8—psoriasis	1.08e-05	0.000186	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—SOCS1—psoriasis	1.07e-05	0.000184	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.07e-05	0.000184	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—CAT—psoriasis	1.04e-05	0.000179	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—TYK2—psoriasis	1.02e-05	0.000176	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—CAT—psoriasis	1.02e-05	0.000175	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—CAT—psoriasis	1.02e-05	0.000175	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—APOE—psoriasis	1e-05	0.000172	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CARM1—psoriasis	9.98e-06	0.000171	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—CXCL8—psoriasis	9.85e-06	0.000169	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—CXCL8—psoriasis	9.82e-06	0.000169	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—TP53—psoriasis	9.78e-06	0.000168	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—CAT—psoriasis	9.63e-06	0.000165	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.33e-06	0.00016	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—IL6—psoriasis	8.95e-06	0.000154	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—CXCL8—psoriasis	8.91e-06	0.000153	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—CAT—psoriasis	8.83e-06	0.000152	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—LEP—psoriasis	8.75e-06	0.00015	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—APOE—psoriasis	8.75e-06	0.00015	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PPARG—psoriasis	8.75e-06	0.00015	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NFKBIA—psoriasis	8.16e-06	0.00014	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—APOE—psoriasis	8.1e-06	0.000139	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—APOE—psoriasis	7.93e-06	0.000136	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—APOE—psoriasis	7.92e-06	0.000136	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—LEP—psoriasis	7.92e-06	0.000136	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—APOE—psoriasis	7.92e-06	0.000136	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CAT—psoriasis	7.88e-06	0.000135	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CARM1—psoriasis	7.7e-06	0.000132	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CAT—psoriasis	7.69e-06	0.000132	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—APOE—psoriasis	7.48e-06	0.000128	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NFKBIA—psoriasis	7.38e-06	0.000127	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CAT—psoriasis	7.25e-06	0.000124	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CAT—psoriasis	7.18e-06	0.000123	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PPARG—psoriasis	7.06e-06	0.000121	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PPARG—psoriasis	6.91e-06	0.000119	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PPARG—psoriasis	6.9e-06	0.000118	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—APOE—psoriasis	6.86e-06	0.000118	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TYK2—psoriasis	6.68e-06	0.000115	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PPARG—psoriasis	6.52e-06	0.000112	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CAT—psoriasis	6.14e-06	0.000105	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—APOE—psoriasis	6.12e-06	0.000105	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TYK2—psoriasis	6.05e-06	0.000104	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—APOE—psoriasis	5.97e-06	0.000103	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PPARG—psoriasis	5.97e-06	0.000103	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CXCL8—psoriasis	5.82e-06	9.99e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—APOE—psoriasis	5.63e-06	9.67e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—APOE—psoriasis	5.58e-06	9.58e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—IL6—psoriasis	5.53e-06	9.5e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—JUN—psoriasis	5.41e-06	9.29e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PPARG—psoriasis	5.33e-06	9.15e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CXCL8—psoriasis	5.27e-06	9.04e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NFKB1—psoriasis	5.21e-06	8.94e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PPARG—psoriasis	5.2e-06	8.94e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—IL6—psoriasis	5.01e-06	8.6e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PPARG—psoriasis	4.9e-06	8.42e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—JUN—psoriasis	4.9e-06	8.41e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PPARG—psoriasis	4.86e-06	8.35e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—APOE—psoriasis	4.77e-06	8.19e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CAT—psoriasis	4.74e-06	8.13e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—VEGFA—psoriasis	4.72e-06	8.11e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NFKB1—psoriasis	4.71e-06	8.09e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—STAT3—psoriasis	4.68e-06	8.03e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—VEGFA—psoriasis	4.28e-06	7.34e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—STAT3—psoriasis	4.23e-06	7.27e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PPARG—psoriasis	4.15e-06	7.13e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—APOE—psoriasis	3.68e-06	6.32e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TP53—psoriasis	3.57e-06	6.13e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IL6—psoriasis	3.27e-06	5.61e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TP53—psoriasis	3.23e-06	5.55e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PPARG—psoriasis	3.21e-06	5.51e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IL6—psoriasis	2.96e-06	5.08e-05	CbGpPWpGaD
